Contribution of the von Willebrand factor/ADAMTS13 imbalance to COVID-19 coagulopathy
- PMID: 34890277
- PMCID: PMC8714251
- DOI: 10.1152/ajpheart.00204.2021
Contribution of the von Willebrand factor/ADAMTS13 imbalance to COVID-19 coagulopathy
Abstract
The 2019 coronavirus disease (COVID-19) is the disease caused by SARS-CoV-2 infection. Although this infection has been shown to affect the respiratory system, a high incidence of thrombotic events has been observed in severe cases of COVID-19 and in a significant portion of COVID-19 nonsurvivors. Although prior literature has reported on both the coagulopathy and hypercoagulability of COVID-19, the specifics of coagulation have not been fully investigated. Observations of microthrombosis in patients with COVID-19 have brought attention to potential inflammatory endothelial injury. Von Willebrand factor (VWF) and its protease, A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13), play an important homeostatic role in responding to endothelial injury. This report provides an overview of the literature investigating the role the VWF/ADAMTS13 axis may have in COVID-19 thrombotic events and suggests potential therapeutic strategies to prevent the progression of coagulopathy in patients with COVID-19.
Keywords: COVID-19; coagulopathy; endothelium; thrombosis; von Willebrand factor.
Conflict of interest statement
No conflicts of interest, financial or otherwise, are declared by the authors.
Figures
References
-
- Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, Kucher N, Studt JD, Sacco C, Bertuzzi A, Sandri MT, Barco S; Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 191: 9–14, 2020. doi:10.1016/j.thromres.2020.04.024. - DOI - PMC - PubMed
-
- Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, Goodarzi K, Bendapudi PK, Bornikova L, Gupta S, Leaf DE, Kuter DJ, Rosovsky RP. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 136: 489–500, 2020. doi:10.1182/blood.2020006520. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- FS/20/9/34989/BHF_/British Heart Foundation/United Kingdom
- R21 AI163708/AI/NIAID NIH HHS/United States
- 133634/HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (DMID)
- R21 HL152348/HL/NHLBI NIH HHS/United States
- R01 HL153986/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
